AMAG cuts hedge fund to stay with Allos
This article was originally published in Scrip
AMAG Pharmaceuticals' board of directors has "unanimously" decided to oppose the unsolicited bid for the company by MSMB Capital Management as it is "not reasonably expected to result in a superior offer to the merger with Allos Therapeutics".
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.